Slide 1: Active Biotech Company presentation
ACTIVE BIOTECH Company presentation
Slide 2: Disclaimer
Disclaimer • Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or i
Slide 3: Active Biotech in brief
Active Biotech in brief Refocused development in specialist disease areas Finance & Corporate • Large unmet medical need and value potential • Listed on Nasdaq Stockholm Small Cap (ticker: ACTI) • Tasquinimod - Haematological malignancies ( Ph I/II studies ongoing) • Market cap SEK 136,3 M, USD 14,3
Slide 4: Targeting cancer and inflammation through immunomodulation
Targeting cancer and inflammation through immunomodulation Tasquinimod Laquinimod Deliberately Helping the body fight reducing harmful back against immune myelofibrosis: responses Small molecules • Restored anti-tumour immunity Myeloid cell • Decreased modulation angiogenesis • Decreased fibrosis •
Slide 5: Valuable project portfolio in cancer and eye disorders
Valuable project portfolio in cancer and eye disorders WHOLLY OWNED PROJECTS Disease Area Discovery Preclinical Phase I Phase II Phase III Partner Hematological Tasquinimod Myelofibrosis malignancies Tasquinimod Myelofibrosis Tasquinimod Multiple myeloma Inflammatory eye Laquinimod Eye drops, safety
Slide 6: Tasquinimod
Tasquinimod Active Ay Biotech /)
Slide 7: Tasquinimod: ODD focus in rare haematological malignancies
Tasquinimod: ODD focus in rare haematological malignancies Core focus Concluded study High value opportunity Myelofibrosis (MF) Multiple myeloma (MM) Myelodysplastic syndrome (MDS) Disease modifying potential Complement to existing treatments Restoration of haematopoiesis • Market size 2.3bn (2021)1
Slide 8: Myelofibrosis: A rare chronic blood cancer
Myelofibrosis: A rare chronic blood cancer Myelofibrosis in brief Key characteristics of myelofibrosis • Myelofibrosis is a rare blood cancer with an incidence of approximately 1.5 cases per 100,000 people and with an estimated prevalence of more than 100,000 patients with myelofibrosis in the EU, U
Slide 9: Myelofibrosis: A major unmet medical need
Myelofibrosis: A major unmet medical need Key market insights 85,000 people • Despite four JAK inhibitors approved there is Total prevalent cases for still: myelofibrosis (primary and • A clear unmet need for disease-modifying secondary MF) therapies • A strong demand for effective second-line optio
Slide 10: Tasquinimod improves hallmarks of myelofibrosis and boosts effects of other therapies
Tasquinimod improves hallmarks of myelofibrosis and boosts effects of other therapies Tasquinimod improves core symptoms of myelofibrosis… …and enhances BET and JAK inhibitor efficacy in advanced myelofibrosis 1 Control Tasquinimod Reduced fibrosis Reduced spleen size2 Reduced spleen size Normalizat
Slide 11: Tasquinimod: Two clinical trials ongoing in myelofibrosis
Tasquinimod: Two clinical trials ongoing in myelofibrosis Ph-Ib/II studies in patients with primary or secondary myelofibrosis TasqForce1 MD Anderson 2 Phase Ib/II trial (N=20) Phase II trial (N=33) Tasquinimod monotherapy in JAKi Tasquinimod monotherapy in JAKi Tasquinimod + JAK inhibitor in inelig
Slide 12: Laquinimod
Active ¢, Biotech )
Slide 13: Laquinimod: First in class topical treatment for eye disorders with unmet medical need
Laquinimod: First in class topical treatment for eye disorders with unmet medical need Core focus High value indications Eye drop formulation enables posterior segment delivery • Proprietary innovative hydrogel eye drop formulation • Eye drop formulation has demonstrated safety, tolerability and eff
Slide 14: Non-infectious uveitis: A significant unmet medical need
Non-infectious uveitis: A significant unmet medical need Standard treatments available today Laquinimod • Corticosteroids: remain the first-line treatment, administered both locally (topical or intravitreal) and systemically • Immunosuppressants: are often used as steroid-sparing agents, especially
Slide 15: Laquinimod works both topically and orally
Laquinimod works both topically and orally Laquinimod reduces Topical laquinimod Oral laquinimod inflammation in experimental uveitis by modulating the immune response: Histological ocular evaluation Topical endoscopic fundus imaging (TEFI) • It lowers levels of pro- ✱✱✱ inflammatory T cells and ✱✱✱
Slide 16: The LION study: Delivery of laquinimod to the posterior parts of the eye
The LION study: Delivery of laquinimod to the posterior parts of the eye Collaboration with Byers Eye Institute, Stanford University School of Medicine Innovative hydrogel eye drop optimized to reach the back of the eye • Principal investigator: MD, Professor Quan Dong Nguyen • Patients undergoing v
Slide 17: Naptumomab
Naptumomab
Slide 18: Naptumomab: Targeted immunotherapy for tumours
Naptumomab: Targeted immunotherapy for tumours Combination with Combination with checkpoint inhibition chemotherapy Pre-clinical data suggest synergy with Pre-clinical data suggest synergy with checkpoint inhibitors chemotherapy • Ph-Ib/IIa combination with anti- • Ph-IIa combination with docetaxel
Slide 19: Conclusion
-“ ° e <- = mm tf - Conclusion
Slide 20: Transforming unmet needs into a market opportunity
Transforming unmet needs into a market opportunity Focused A portfolio of immunomodulating assets within oncology and inflammation with significant unmet pipeline needs Regulatory Orphan Drug Designation for tasquinimod in myelofibrosis and multiple myeloma, securing e.g. 7 advantage years of market
Slide 21: Appendix
APPENDIX
Slide 22: Financials for the period January – June 2026
Financials for the period January – June 2026 Operating costs by quarter 2025 - 2026 MSEK Liquidity (MSEK) 65.1 53.3 7.6 8.2 6.7 43.9 6.1 5.8 3.3 26.2 3.7 3.0 3.5 16.8 3.0 2.7 2.8 9.1 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 MAR 31 2025 JUNE 30 2025 SEPT 30 2025 DEC 31 2025 MAR 31 2026 JUNE 30 2026 Adm.
Slide 23: Meet the management team
Meet the management team Helén Tuvesson Hans Kolam Erik Vahtola CEO CFO CMO Born: 1962 Born: 1951 Born: 1976 CEO since 2017 CFO since 2000 CMO since 2022 Education: MSc, PhD in cell and molecular Education: B.Sc in Business Administration Education: Medical Doctor (MD) and PhD in biology in medical
Slide 24: Board of directors
Board of directors Michael Shalmi Alexandar Danilovski Peter Thelin Chairman of the Board Board member Board member Born 1965 Born 1974 Born 1956 Chairman of the board since 2019 Board member since 2020 Board member since 2011 Education: Education: Education: Physician from University of Copenhagen
Slide 25: www.activebiotech.com
Active ¢ Biotech f) www.activebiotech.com